Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of intra-articular resiniferatoxin (RTX-GRT7039) for knee osteoarthritis pain
2021-005029-26Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Apr 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) and osteoarthritis (OA) comparing RTX-GRT7039 with Placebo (2 arms). Primary endpoint: Change in WOMAC pain subscale score (index knee). Started Apr 2022; status: completed.
02
Drugs
resiniferatoxin
03
Conditions
knee osteoarthritis (OA)osteoarthritis (OA)
Beyond the preview
Go deeper on 2021-005029-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005029-26.